PharmaCyte Biotech, Inc. 8-K
Research Summary
AI-generated summary
PharmaCyte Biotech Reports Annual Meeting Results; 2M-Share Plan Increase
What Happened
PharmaCyte Biotech, Inc. (PMCB) filed an 8-K reporting results of its March 30, 2026 annual meeting. Shareholders approved an amendment to the company’s 2022 Equity Incentive Plan to add 2,000,000 shares for awards, ratified CBIZ CPAs P.C. as the independent auditor for fiscal 2026, approved a board-authority amendment to allow a reverse stock split (ratios between 1-for-1.1 and 1-for-100), and re-elected five directors. Approximately 7,387,861 shares (about 55.08% of outstanding voting stock) were represented, establishing a quorum.
Key Details
- Annual meeting date: March 30, 2026; quorum: 7,387,861 shares (≈55.08%).
- Equity plan amendment: approved increase of 2,000,000 shares to the 2022 Equity Incentive Plan (full amended plan filed as Exhibit 10.1). Vote: For 3,133,280; Against 804,435; Abstain 9,572.
- Director elections: five directors re-elected to hold office through the 2027 annual meeting — Joshua N. Silverman; Jonathan L. Schechter; Michael M. Abecassis; Robert Weinstein; Wayne R. Walker (vote tallies included in filing).
- Other votes: Ratified CBIZ CPAs P.C. as independent registered public accounting firm (For 6,837,442; Against 514,469; Abstain 35,950). Non-binding approval of executive compensation (For 3,306,883; Against 625,080; Abstain 15,322). Reverse split authority amendment approved (For 5,067,304; Against 2,280,497; Abstain 40,056).
Why It Matters
The approved 2,000,000-share increase gives PharmaCyte flexibility to grant more equity awards (stock options, restricted stock, etc.), which could result in future share issuance and potential dilution for current shareholders if awards are granted and vested. The reverse-split amendment simply gives the board the option — not an obligation — to consolidate shares at a ratio between 1.1-to-1 and 100-to-1, a tool companies sometimes use to meet listing requirements or change per-share trading price. Ratification of the auditor and re-election of the board indicate continuity in oversight and governance.
Loading document...